Abstracts tagged "SLE"

Abstract Number: 726 • 2015 ACR/ARHP Annual Meeting
Associates of Pleurisy of Pericarditis in Systemic Lupus Erythematosus (SLE)
Seungwon Ryu¹ and Michelle Petri², ¹Konkuk University School of Medicine, Seoul, South Korea, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Serositis is one of the classification criteria for systemic lupus erythematosus and a common type of extra renal flare. Comparison of associates of pleurisy…
Abstract Number: 810 • 2015 ACR/ARHP Annual Meeting
Human Parvovirus B19 Nonstructural Protein 1 (NS1) Helicase Breaks Tolerance to Self dsDNA: A Model for Viral Induction of Autoimmunity
Heidi Pirttinen¹, Kanoktip Puttaraksa¹, Robert J. Lagier², Stanley J. Naides³ and Leona Gilbert¹, ¹Department of Biological and Environmental Science, University of Jyväskylä, Jyväskylä, Finland, ²Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ³Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA
Background/Purpose: B19 virus (B19V) is common, infects all ages, and is associated with various clinical syndromes including SLE-like autoimmunity. We previously demonstrated that B19 NS1,…
Abstract Number: 1760 • 2015 ACR/ARHP Annual Meeting
PD-1 Signaling Interferes with OX40 to Alter the Suppressive Function and Proliferation of CD4+ Regulatory T Cells in Lupus Mice
Maida Wong¹ and Bevra H. Hahn^2,3, ¹Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, ²Medicine, UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ³Rheumatology, Professor Emeritus, Department of Medicine/Rheumatology, David Geffen School of Medicine UCLA, Los Angeles, CA
Background/Purpose: In systemic lupus erythematosus (SLE), the dysregulated production of autoantibodies is a consequence of disrupted T cell homeostasis. Programmed death-1 (PD1), a negative regulatory…
Abstract Number: 1859 • 2015 ACR/ARHP Annual Meeting
Anti-Interferon Autoantibodies in Systemic Lupus Erythematosus Are Biologically Active and Have Distinct Functions
Sarthak Gupta^1,2, Ioanna P. Tatouli³, Lindsey B. Rosen¹, Sarfaraz Hasni², Illias Alevizos⁴, Zerai G. Manna², Juan Rivera², Chao Jiang^2,5, Richard M. Siegel⁶, Steven M. Holland¹, Haralampos M. Moutsopoulos³ and Sarah K. Browne^1,7, ¹Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ⁴National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, ⁵National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD, ⁶NIAMS, Immunoregulation Section, Autoimmunity Branch, Bethesda, MD, ⁷Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD
Background/Purpose: Anticytokine autoantibodies are pathogenic in many hematologic, pulmonary and infectious diseases. However, a systematic investigation of their presence and significance in autoimmune diseases is…
Abstract Number: 2933 • 2015 ACR/ARHP Annual Meeting
Low Prevalence of PCP in Hospitalized Patients with SLE: Review of a Clinical Database Warehouse
Teja Kapoor¹, Jianhua Li², Sameer Malhotra³, Joan Bathon⁴ and Anca Askanase⁵, ¹Columbia University, New York, NY, ²Columbia University Medical Center, New York, NY, ³Weill Cornell Medical Center, New York, NY, ⁴Rheumatology, Columbia University Medical Center, NY, NY, ⁵Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose : The risk of Pneumocystis carinii pneumonia (PCP) in Systemic Lupus Erythematosus (SLE) is not well-established. Accordingly, this study aims to establish the prevalence…
Abstract Number: 733 • 2015 ACR/ARHP Annual Meeting
Late Onset Systemic Lupus Erythematosus: A Different Disease Subset?
Anne Riveros Frutos¹, Melania Martínez-Morillo¹, Irma Casas^2,3, Iñigo Rúa-Figueroa⁴, JM Pego-Reigosa⁵, M. Jesús García de Yebenes⁶, Alejandro Olivé¹, José Rosas⁷, Paloma Vela Casasempere⁸, Monica Ibanez Barcelo⁹, Vicente Torrente¹⁰, Ivan Castellvi¹¹, Javier Narváez¹², Mireia Moreno¹³, Ricardo Blanco¹⁴, Víctor Martínez Taboada¹⁵, Jaime Calvo¹⁶, Ángeles Aguirre Zamorano¹⁷, Mercedes Freire¹⁸, Enrique Raya¹⁹, Celia Erausquin²⁰, Esther Uriarte²¹, Elvira Diez Alvarez²², Tomás Vázquez Rodríguez²³, Antonio Fernandez-Nebro²⁴, Eva Tomero²⁵, Paloma García de la Peña²⁶, Ana Sánchez Atrio²⁷, Monica Fernandez Castro²⁸, Antonio Zea²⁹, Patricia Richi³⁰, Francisco Javier López Longo³¹, María Galindo³², Patricia E. Carreira³³, Gema Bonilla³⁴, Carlos Marras Fernandez-Cid³⁵, Maria Loreto Horcada³⁶, Carlos Alberto Montilla Morales³⁷, Blanca Hernández-Cruz³⁸, José Luis Marenco de la Fuente³⁹, Marian Gantes⁴⁰, Olaia Fernández Berrizbeitia⁴¹, Juan José Alegre⁴², Ángela Pecondón Español⁴³, Manuel Rodríguez-Gómez⁴⁴, Victor Quevedo⁴⁵, José Hernández Beiraín⁴⁶ and Lucía Silva Fernández⁴⁷, ¹Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ²Preventive Medicine, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ³preventive medicine, Hospital Universitari Germans Trias i Pujol, barcelona, Spain, ⁴Rheumatology, Hospital Universitario Dr. Negrin, Las Palmas de Gran Canarias, Spain, ⁵Rheumatology, Hospital Meixoeiro, Vigo, Spain, ⁶Research Unit of the SER, Madrid, Spain, ⁷Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ⁸Rheumatology, Hospital General de Alicante, Alicante, Spain, ⁹H. Son Llatzer, Palma de Mallorca, Spain, ¹⁰Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain, ¹¹Unitat de Reumatologia., Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹²Rheumatology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ¹³Rheumatology, Hospital Parc Taulí, Sabadell, Spain, ¹⁴Reumatologia, Hospital Universitario Marques de Valdecilla, Santander, Spain, ¹⁵Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ¹⁶Rheumatology, Hospital de Sierrallana, Torrelavega, Spain, ¹⁷Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ¹⁸Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹⁹Rheumatology, Hospital Clínico San Cecilio, Granada, Spain, ²⁰Rheumatology, Hospital de Gran Canaria Dr Negrin, Las Palmas GC, Spain, ²¹Reumatología, Hospital de Donosti, Donosti, Spain, ²²Rheumatology, Hospital de León, León, Spain, ²³Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ²⁴Rheumatology, Hospital Universitario Carlos Haya, Malaga, Spain, ²⁵Hospital La Princesa. Madrid., Madrid, Spain, ²⁶Rheumatology, Hospital Universitario Madrid Norte Sanchinarro, Madrid, Spain, ²⁷Hospital Principe de Asturias. Madrid, Madrid, Spain, ²⁸Rheumatology, Hospital Puerta de Hierro, Madrid, Spain, ²⁹Hospital Ramón y Cajal, Madrid, Spain, ³⁰Hospital Infanta Sofía, Madrid, Spain, ³¹Hospital Gregorio Marañón, Madrid, Spain, ³²Rheumatology, Hospital 12 de octubre, Madrid, Spain, ³³Hospital 12 de Octubre, Madrid, Spain, ³⁴Rheumatology, Hospital La Paz, Madrid, Spain, ³⁵Hospital Virgen de la Arrixaca, Murcia, Spain, ³⁶Rheumatology, Complejo Hospitalario de Navarra, Pamplona, Spain, ³⁷Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ³⁸Rheumatology, Hospital Universitario Virgen Macarena, Sevilla, Spain, ³⁹Rheumatology, Hospital de Valme, Seville, Spain, ⁴⁰Hospital Universitario de Canarias, Tenerife, Spain, ⁴¹Rheumatology, Basurto University Hospital, Bilbao, Spain, ⁴²Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, ⁴³Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ⁴⁴Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ⁴⁵Rheumatology, Hospital de Monforte, Lugo, Spain, ⁴⁶Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ⁴⁷Hospital Universitario de Guadalajara, Guadalajara, Spain
Background/Purpose: To describe the demographic, clinical and immunological manifestations in patients with late onset systemic lupus erythematosus (SLE) Methods: Patients diagnosed of SLE in the RELESSER data…
Abstract Number: 812 • 2015 ACR/ARHP Annual Meeting
SLAMF3 Mediated Co-Stimulation Promotes Activation of the IL-2/IL-2R/STAT5 Pathway and Regulatory T Cells Differentiation in Human Naïve CD4+ T Cells – Implications for SLE
Denis Comte^1,2, Maria P. Karampetsou¹, Katalin Kis-Toth¹, Nobuya Yoshida¹, Julie Solomon¹, Vasileios C. Kyttaris¹ and George C. Tsokos¹, ¹Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Background/Purpose: SLE is a multisystem autoimmune disease that displays quantitative and qualitative deficiencies of regulatory T cells (Treg), notably because of a compromised IL-2 production.…
Abstract Number: 1770 • 2015 ACR/ARHP Annual Meeting
A New Perspective in Extracorporeal Immunotherapy of Systemic Lupus Erythematosus: Dnase I-Based Blood Perfusion Experiment Using Rat Model
Ekaterina Simakova, Andrey Trofimenko, Ilya Gontar and Irina Zborovskaya, Research Institute of Clinical and Experimental Rheumatology, Volgograd, Russia
Background/Purpose: DNA, nucleosomes, and other deoxyribonucleoproteins (DNP) are currently believed to be the key autoantigens in SLE. However, these extracellular DNP itself appear to be…
Abstract Number: 1862 • 2015 ACR/ARHP Annual Meeting
Identification of Homogeneous Systemic Lupus Erythematosus (SLE) Patient Groups Using Clustered Autoantibody Reactivities
Petra Budde¹, Hans-Dieter Zucht¹, Daniel Chamrad¹, Anna Telaar¹, Johannes Schulte-Pelkum¹, Stefan Vordenbäumen², Peter Schulz-Knappe¹ and Matthias Schneider³, ¹Protagen AG, Dortmund, Germany, ²Department of Rheumatology, Univ. Duesseldorf, Düsseldorf, Germany, ³Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: In SLE, early diagnosis, differentiation to other autoimmune diseases and prognostic stratification are still great challenges. Hence, SLE represents an enormous challenge for the…
Abstract Number: 2944 • 2015 ACR/ARHP Annual Meeting
Presepsin (sCD14 subtype) Concentration Is Elevated and Reflects Disease Activity in Systemic Lupus Erythematous Patients
Kohei Tsujimoto¹, Masaaki Fujita², Yutaka Shinkawa², Iku Shirasugi¹, Masashi Taniguchi¹, Saori Hatachi³ and Masato Yagita⁴, ¹Department of Clinical Immunology and Rheumatology, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan, ²Department of Clinical Immunology and Rheumatology C, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan, ³Department of Rheumatology, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan, ⁴Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan
Background/Purpose: Presepsin (sCD14 subtype) has recently been identified as a novel biomarker for predicting sepsis. Because presepsin is produced as a consequence of cellular phagocytosis,…
Abstract Number: 734 • 2015 ACR/ARHP Annual Meeting
Disease Patterns, Flare Incidence and Organ Damage Among Filipino Patients with Systemic Lupus Erythematosus: a One-Year Observational Study
Mary Flor Joy Edar, Leonid Zamora, Catherine Macapagal and Sandra V. Navarra, Rheumatology, University of Santo Tomas Hospital, Manila, Philippines
Background/Purpose: This study describes the disease patterns, flare incidence, hospitalizations and causes of mortality in a cohort of Filipino patients with systemic lupus erythematosus (SLE),…
Abstract Number: 817 • 2015 ACR/ARHP Annual Meeting
Circulating Endothelial Cell (CEC) and CEC-Bound C4d Levels As Biomarkers of Systemic Lupus Erythematosus
Chau-Ching Liu¹, Susan Manzi² and Joseph Ahearn³, ¹Allegheny Singer Research Institute, Pittsburgh, PA, ²Rheumatology, Allegheny Health Network, Pittsburgh, PA, ³Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Accelerated atherosclerotic disease has been widely recognized in patients with SLE. Circulating endothelial cells (CECs) are a rare cell population believed to detach from…
Abstract Number: 1773 • 2015 ACR/ARHP Annual Meeting
Pan JAK Inhibitor Tofacitinib Ameliorate Autoimmunity and Nephritis in Lupus Prone Mice Via Inhibition of Interferon Signaling Pathway
Keigo Ikeda^1,2, Kunihiro Hayakawa², Maki Fujishiro³, Mikiko Kawasaki³, Takuya Hirai^2,4, Shinji Morimoto^2,4, Yoshinari Takasaki⁵ and Iwao Sekigawa^3,4, ¹Department of Internal Medicine and Rheumatology, Juntendo University Urayasu Hospital, Tomioka, Urayasu, Chiba, Japan, ²Institute for Environmental and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan, ³Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University Urayasu Hospital, Chiba, Japan, ⁵Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: We previously reported that Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway-mediated regulation of interferon (IFN) regulatory factor (IRF)-related genes may have an…
Abstract Number: 1867 • 2015 ACR/ARHP Annual Meeting
Functional Androgen Receptor Variants Associated with Greater Damage in Systemic Lupus Erythematosus
Yun Deng¹, Jennifer M. Grossman^1,2, Qiong Fu¹, William J. Martin¹, Judith A. James³, Joan T. Merrill⁴, Diane L. Kamen⁵, Gary S. Gilkeson⁵, Susan A. Boackle⁶, Chaim Putterman⁷, Jane E. Salmon⁸, Vasileios C. Kyttaris⁹, George C. Tsokos⁹, Matthew Quirk¹⁰, Seema Kamble¹, Melissa Barcelona¹, Erika Magdangal¹⁰, Lori Sahakian¹¹, Seung Yoon Lee¹, Tracy Y. Lin¹, Weiling Chen¹, Jennifer M.P. Woo¹², Ornella J. Rullo¹², Deborah K. McCurdy¹², Bevra H. Hahn^13,14, Maureen A. McMahon¹¹, Sang-Cheol Bae¹⁵ and Betty P. Tsao¹, ¹Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ²Rheumatology, UCLA, Los Angeles, CA, ³Arthritis and Clinical Immunology, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁷Division of Rheumatology, Albert Einstein College of Medicine, New York, NY, ⁸Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁹Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ¹⁰Division of Rheumatology, Department of Medicine,, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ¹¹Division of Rheumatology, Department of Medicine, UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ¹²Pediatric Rheumatology, Mattel Children's Hospital, University of California Los Angeles, Los Angeles, CA, ¹³Medicine, UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ¹⁴Rheumatology, Professor Emeritus, Department of Medicine/Rheumatology, David Geffen School of Medicine UCLA, Los Angeles, CA, ¹⁵Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose :Organ damage predicts physical disability and mortality of SLE. Given that men with SLE tend to develop accelerated damage, we selected an X-linked androgen…
Abstract Number: 2947 • 2015 ACR/ARHP Annual Meeting
Association of Anti-NR2 and U1RNP Antibodies with Neurotoxic Inflammatory Mediators in Cerebrospinal Fluid from Patients with Neuropsychiatric Systemic Lupus Erythematosus
Seiko Kondo-Ishikawa¹, Takao Fujii², Nozomi Ishigooka¹, Kosaku Murakami¹, Ran Nakashima¹, Yoshitaka Imura¹, Motomu Hashimoto², Naoichiro Yukawa¹, Hajime Yoshifuji¹, Koichiro Ohmura¹ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of the Control for Rheumatic Diseases, Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Autoantibodies (auto Abs) in cerebrospinal fluid (CSF) and inflammatory mediators (IMs) may be involved in the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE). Previous…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].